Economics of Treatments for Non-Small Cell Lung Cancer

@article{Chouaid2009EconomicsOT,
  title={Economics of Treatments for Non-Small Cell Lung Cancer},
  author={Prof. Christos Chouaid and Kukovi Atsou and Gilles Hejblum and Alain Vergnen{\`e}gre},
  journal={PharmacoEconomics},
  year={2009},
  volume={27},
  pages={113-125}
}
The purpose of this article is to review the economics of treatments for non-small cell lung cancer (NSCLC). We systematically analysed the cost effectiveness of treatments for the different stages of NSCLC, with particular emphasis on more recently approved agents. Numerous economic analyses in NSCLC have been conducted, with a variety of methods and in a number of countries. In patients with localized disease, adjuvant chemotherapy appears to have greater cost effectiveness than observation… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 64 references

Cost-effectiveness of erlotinib compared with docetaxel for the treatment of relapsed non small cell lung cancer (SNCL) in UK [abstract

  • G Lewis, L Morlotti, J Creeden
  • Value Health 2006;
  • 2006
Highly Influential
4 Excerpts

Cost-effectiveness of permetrexed for previously treated advanced non-small cell lung cancer

  • N Pavlakis, PL Mitchell, G. Stynes
  • American Society of Clinical Oncology
  • 2005
Highly Influential
15 Excerpts

Similar Papers

Loading similar papers…